These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 17373187)

  • 41. Psoriasis--recent advances in understanding its pathogenesis and treatment.
    Krueger G; Ellis CN
    J Am Acad Dermatol; 2005 Jul; 53(1 Suppl 1):S94-100. PubMed ID: 15968269
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and Therapeutic Evaluation of Patients with Moderate to Severe Psoriasis in Spain: The Secuence Study.
    Hernánz JM; Sánchez-Regaña M; Izu R; Mendiola V; García-Calvo C
    Actas Dermosifiliogr; 2012 Dec; 103(10):897-904. PubMed ID: 22748300
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial.
    Flytström I; Stenberg B; Svensson A; Bergbrant IM
    Br J Dermatol; 2008 Jan; 158(1):116-21. PubMed ID: 17986302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decision points for the initiation of systemic treatment for psoriasis.
    Feldman SR; Koo JY; Menter A; Bagel J
    J Am Acad Dermatol; 2005 Jul; 53(1):101-7. PubMed ID: 15965429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors affecting response to biologic treatment in psoriasis.
    Karczewski J; Poniedziałek B; Rzymski P; Adamski Z
    Dermatol Ther; 2014; 27(6):323-30. PubMed ID: 25053228
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phototherapy, psoriasis, and the age of biologics.
    Richard EG; Hönigsmann H
    Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Topical corticosteroids and corticosteroid sparing therapy in psoriasis management].
    Sukarovska BG; Lipozencić J; Vrzogić P
    Acta Med Croatica; 2007 Sep; 61(4):375-81. PubMed ID: 18044472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
    Christophers E; Segaert S; Milligan G; Molta CT; Boggs R
    J Dermatolog Treat; 2013 Jun; 24(3):193-8. PubMed ID: 22620684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Compatibility of topical therapies for psoriasis: challenges and innovations.
    Lebwohl MG; Corvari L
    Cutis; 2007 Jan; 79(1 Suppl 2):5-10. PubMed ID: 17367040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
    Rich SJ
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
    Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
    Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insight into psoriasis management: commercial perspectives for the U.S. psoriasis market.
    Tran B; Feldman SR
    J Dermatolog Treat; 2011 Feb; 22(1):18-26. PubMed ID: 20528668
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation of etanercept in the management of chronic plaque psoriasis.
    Lloyd A; Reeves P; Conway P; Reynolds A; Baxter G
    Br J Dermatol; 2009 Feb; 160(2):380-6. PubMed ID: 18808413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
    Puig L; Bordas X; Carrascosa JM; Daudén E; Ferrándiz C; Hernanz JM; López-Estebaranz JL; Moreno JC; Sánchez-Carazo JL; Vanaclocha F; Vázquez-Veiga H;
    Actas Dermosifiliogr; 2009 May; 100(4):277-86. PubMed ID: 19463230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Topical treatments for psoriasis in 2009].
    Thielen AM; Laffitte E
    Rev Med Suisse; 2009 Apr; 5(200):876, 878-81. PubMed ID: 19438087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of topical calcitriol 3 microg/g ointment, a new topical therapy for chronic plaque psoriasis.
    Kircik L
    J Drugs Dermatol; 2009 Aug; 8(8 Suppl):s9-16. PubMed ID: 19702031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
    Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
    J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Strober B; Gooderham M; de Jong EMGJ; Kimball AB; Langley RG; Lakdawala N; Goyal K; Lawson F; Langholff W; Hopkins L; Fakharzadeh S; Srivastava B; Menter A
    J Am Acad Dermatol; 2018 Jan; 78(1):70-80. PubMed ID: 29102053
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Satisfaction with treatment among patients with psoriasis: a web-based survey study.
    van Cranenburgh OD; de Korte J; Sprangers MA; de Rie MA; Smets EM
    Br J Dermatol; 2013 Aug; 169(2):398-405. PubMed ID: 23565643
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients.
    Takahashi H; Iinuma S; Tsuji H; Honma M; Iizuka H
    J Dermatol; 2014 Aug; 41(8):686-9. PubMed ID: 25040258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.